Ligand Pharmaceuticals Incorporated
LGND
$213.21
-$5.77-2.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 51.24% | 60.40% | 64.83% | 40.54% | 53.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.24% | 60.40% | 64.83% | 40.54% | 53.40% |
| Cost of Revenue | -41.18% | 194.57% | 198.12% | 139.92% | 134.41% |
| Gross Profit | 121.81% | 28.02% | 28.89% | 7.55% | 21.37% |
| SG&A Expenses | 9.23% | 17.54% | 34.74% | 50.38% | 63.57% |
| Depreciation & Amortization | -1.46% | -0.76% | -0.51% | 0.04% | -0.81% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.55% | 53.28% | 65.41% | 60.86% | 65.50% |
| Operating Income | 708.84% | 105.03% | 60.47% | -279.21% | -1,090.97% |
| Income Before Tax | 214.76% | 6,212.95% | 7.08% | -259.40% | -232.52% |
| Income Tax Expenses | 209.95% | 426.82% | 6.10% | -179.43% | -212.92% |
| Earnings from Continuing Operations | 215.79% | 3,186.63% | 7.38% | -280.02% | -237.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 215.79% | 3,186.63% | 7.38% | -280.02% | -237.65% |
| EBIT | 708.84% | 105.03% | 60.47% | -279.21% | -1,090.97% |
| EBITDA | 624.61% | 39.78% | 18.67% | -54.05% | -46.45% |
| EPS Basic | 210.12% | 12,799.80% | -9.12% | -264.26% | -230.86% |
| Normalized Basic EPS | 342.33% | 438.58% | -371.44% | -809.82% | -2,875.49% |
| EPS Diluted | 203.39% | 3,710.73% | -17.72% | -273.26% | -233.88% |
| Normalized Diluted EPS | 329.31% | 412.51% | -424.68% | -818.03% | -2,933.86% |
| Average Basic Shares Outstanding | 5.23% | 6.38% | 7.57% | 7.51% | 6.81% |
| Average Diluted Shares Outstanding | 9.33% | 9.98% | 8.96% | 7.45% | 5.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |